Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Raised by Federated Hermes Inc.

Federated Hermes Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 232,785 shares of the medical equipment provider’s stock after purchasing an additional 17,545 shares during the period. Federated Hermes Inc. owned about 0.11% of Zimmer Biomet worth $28,330,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Schechter Investment Advisors LLC grew its position in shares of Zimmer Biomet by 21.6% in the 3rd quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock worth $476,000 after acquiring an additional 752 shares in the last quarter. Atria Wealth Solutions Inc. increased its stake in Zimmer Biomet by 5.9% during the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock valued at $2,312,000 after purchasing an additional 1,144 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Zimmer Biomet by 11,244.9% during the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock worth $8,146,000 after purchasing an additional 66,345 shares during the period. Amalgamated Bank lifted its position in shares of Zimmer Biomet by 3.0% in the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after buying an additional 1,631 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Zimmer Biomet by 37.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock valued at $18,981,000 after buying an additional 42,539 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.95% of the stock is owned by insiders.

Zimmer Biomet Stock Performance

ZBH opened at $119.43 on Friday. The business has a fifty day simple moving average of $126.33 and a 200-day simple moving average of $119.22. The firm has a market cap of $24.54 billion, a PE ratio of 24.42, a P/E/G ratio of 2.19 and a beta of 1.01. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter last year, the business posted $1.88 EPS. Zimmer Biomet’s revenue was up 6.3% on a year-over-year basis. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Analyst Ratings Changes

A number of brokerages have issued reports on ZBH. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 9th. Barclays upped their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. Truist Financial raised their target price on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research note on Friday, February 9th. Evercore ISI increased their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, Citigroup boosted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.